Business Wire

Syncron Accelerates Growth by Joining the AWS ISV Accelerate Program

23.1.2025 14:00:00 CET | Business Wire | Press release

Share

Syncron, a leading provider of intelligent Service Lifecycle Management solutions, announced today that it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program. This co-sell program supports AWS Partners that offer software solutions running on or integrating with AWS, connecting them with the AWS Sales organization to drive new business and accelerate sales cycles.

Unlocking New Growth Opportunities with AWS

By joining the AWS ISV Accelerate Program, Syncron gains focused co-selling support from AWS, as well as access to sales enablement resources, including educational events and solution libraries. Through this partnership, Syncron will collaborate closely with AWS Sales teams, providing better customer outcomes through its integrated and optimized cloud solutions for after-sales services.

Joining the program also enhances Syncron's visibility within the AWS ecosystem, ensuring that AWS Account Managers can actively support the promotion and sale of Syncron’s solutions, benefiting both current and prospective customers.

Claire Rychlewski, Chief Revenue Officer at Syncron, commented on Syncron’s strengthened relationship with AWS: “Being part of the AWS ISV Accelerate Program is a game-changer for Syncron. This collaboration means our solutions are now fully aligned with the AWS commitment to supporting software providers in driving innovative customer-focused outcomes. The opportunity to co-sell with AWS opens new avenues for growth and makes it easier for our customers to access our solutions directly through the AWS Marketplace.”

Through the AWS Marketplace, Syncron customers will gain numerous benefits, including a streamlined procurement process, improved licensing flexibility, and procurement efficiencies that translate into time and cost savings. Customers will also be able to leverage their existing AWS budget allocations to purchase Syncron's AI-powered service lifecycle management solutions, making it easier for organizations already working with AWS to benefit from Syncron's software offerings. Syncron's AI-powered Service Lifecycle Management (SLM) solutions help OEMs and distributors in the automotive, construction, mining, agricultural and industrial equipment, medical devices, consumer durables, high tech, aerospace and other industries successfully transition to future service-driven business models by optimizing service quality and delivery to increase customer loyalty. With more than $3 billion in annual value creation, Syncron connects and synchronizes every aspect of aftermarket service.

In just under eight months, Syncron has progressed from listing its Software as a Service (SaaS) products on AWS Marketplace to joining the ISV Accelerate Program – a notable achievement that highlights Syncron's commitment to advancing strategic partnerships and delivering value to customers worldwide.

About Syncron

Syncron helps manufacturers and distributors capitalize on the new service economy by increasing customer loyalty and optimizing aftermarket profitability. Syncron's integrated, scalable, state-of-the-art Service Lifecycle Management (SLM) cloud platform puts data at the heart of aftermarket operations to unlock service synergies, significant revenue opportunities and help companies differentiate themselves with exceptional aftermarket customer experiences. The world’s top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more, visit syncron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250123527061/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye